NO-dependent vasodilation and deep tumor penetration for cascade-amplified antitumor performance

J Control Release. 2022 Jul:347:389-399. doi: 10.1016/j.jconrel.2022.05.022. Epub 2022 May 18.

Abstract

Nonspecific biodistribution and poor permeability of conventional therapeutic agents in solid tumors severely compromised the antitumor efficacy. Herein, we report a cascade tumor therapeutic nanoplatform consisting of docosahexaenoic acid (DHA) and nicorandil (NI), namely DNP, to specifically produce cytotoxic agents in tumor cells as well as dilating blood vessels to increase the intratumoral oxidative stress levels. The DHA embedded in the membrane could generate reactive oxygen species (ROS) meanwhile NI produced nitric oxide (NO) in response to intracellular glutathione (GSH) in tumors. Notably, the two functional species could further react in situ to form a more tumoricidal reactive nitrogen species (RNS), causing selectively cascade amplification of antitumor performance. In addition, NO-induced vasodilation could consequently result in a series of functions, including hypoxia relief and deep tumor transportation. In general, we anticipate that the DNP could show great potential for tumor-specific treatment by selectively producing RNS precursors in response to the interior environment of tumor cells for hypoxia normalization and tumor inhibition.

Keywords: Deep tumor penetration; Dilating blood vessels; Nitric oxide; Reactive nitrogen species; Tumor-specific therapeutic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Glutathione / metabolism
  • Humans
  • Hypoxia
  • Nitric Oxide*
  • Reactive Nitrogen Species
  • Reactive Oxygen Species
  • Tissue Distribution
  • Vasodilation*

Substances

  • Reactive Nitrogen Species
  • Reactive Oxygen Species
  • Nitric Oxide
  • Glutathione